The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.

Abstract

Several recent clinical trials for high-grade gliomas have demonstrated promising results. Nonetheless, despite improvement in survival, these patients ultimately die of tumor progression. Malignant glioma patients are profoundly immunosuppressed, and a fundamental understanding of which types of glioma have immune resistance mediated by Tregs is required for developing and initiating specific immunotherapeutic approaches that may target these cells.